Evaluating the Level of Serum IL-23 in Brucellosis Infection by ELISA and Investigating its Relationship in Cases with Failure to Respond to Treatment

Document Type : Original Articles


1 Department of Pharmacy, Al-Hadba University College, Mosul, Iraq

2 College of technical engineering, The Islamic University, Najaf, Iraq

3 Department of Optics Techniques, Dijlah University College, Al-Masafi Street, Al-Dora, Baghdad 00964, Iraq

4 Medical laboratory techniques Department, Medical (Technology) College, Al-Farahidi University, Baghdad, Iraq

5 Al-Nisour University College, Baghdad, Iraq

6 Anesthesia Techniques Department, Al-Mustaqbal University College, Babylon, Iraq

7 Al-Manara College For Medical Sciences, Misan, Iraq

8 Al-Esraa University College, Baghdad, Iraq

9 College of Health and Medical Technology, Al-Ayen University, Thi-Qar, Iraq

10 Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq

11 Medical Laboratory Techniques Department, Hilla University College, Babylon, Iraq


Brucella is belonging to the small immobile gram-negative spore-lacking cocco-bacilli bacteria family that grows in an aerobic environment, it is known as a zoonosis infection named brucellosis. This study was designed to investigate serum values of IL-23 in patient with brucellosis and investigate its relationship with cases with failure to respond to conventional medical therapy. A total of 372 individuals were divided into 2 groups (n=186) as follows: Group A comprising 186 infected participants with brucella (7-80 years-old), these people had not received antibiotics for at least 6 months ago. Group B including the healthy participants. All the participants in both groups were in the same age range. 5 ml blood samples were obtained from the participants intravenously (without anticoagulation substance). The serum level of IL-23 was investigated by ELISA diagnostic kit. The recorded data showed that the levels of IL-23 in the serum samples obtained from group A (143.64 Pg/ml) significantly (P<0.001) increased compared with this value in group B (23.14 Pg/ml). Based on the recorded data in the forms completed by all the participants at the day 0 of the experiment, 44 out of 186 individuals in group A, had experienced Brucellosis attack 2-3 times in spite of receiving medical prescriptions. A hypothesis about the possible immune system disorders in these participants lead us to did the re-sampling following drug administration. Results illustrated failure to respond to conventional medical therapy in patients with low level of serum IL-23.


Main Subjects

  1. Głowacka P, Żakowska D, Naylor K, Niemcewicz M, Bielawska-Drózd A. Brucella - Virulence Factors, Pathogenesis and Treatment. Pol J Microbiol. 2018;67(2):151-61.
  2. Diacovich L, Gorvel J-P. Bacterial manipulation of innate immunity to promote infection. Nat Rev Microbiol. 2010;8(2):117-28.
  3. Arnow PM, Smaron M, Ormiste V. Brucellosis in a group of travelers to Spain. JAMA. 1984;251(4):505-7.
  4. Gedikoglu S, Helvaci S, Özakm C, Gökirmak F, Kiliçturgay K. Detection of Brucella melitensis by BACTEC NR 730 and BACTEC 9120 systems. Eur J Epidemiol. 1996;12(6):649-50.
  5. Yagupsky P. Detection of Brucella melitensis by BACTEC NR660 blood culture system. J Clin Microbiol. 1994;32(8):1899-901.
  6. Hasanjani Roushan MR, Ebrahimpour S. Human brucellosis: An overview. 2015.
  7. Bosilkovski M, Arapović J, Keramat F. Human brucellosis in pregnancy–An overview. Bosn J Basic Med Sc. 2020;20(4):415.
  8. Chauhan P, Nair A, Patidar A, Dandapat J, Sarkar A, Saha B. A primer on cytokines. Cytokine. 2021;145:155458.
  9. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp. 2015;63(6):435-49.
  10. Lin X, Söderhäll I. Crustacean hematopoiesis and the astakine cytokines. Blood. 2011;117(24):6417-24.
  11. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova J-L, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719-29.
  12. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
  13. Wang X, Lin Z, Wei Q, Jiang Y, Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int. 2009;29(11):1343-7.
  14. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467-76.
  15. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763-76.
  16. Yang CY, Ma X, Tsuneyama K, Huang S, Takahashi T, Chalasani NP, et al. IL‐12/Th1 and IL‐23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology. 2014;59(5):1944-53.
  17. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin-23 drives innate and T cell–mediated intestinal inflammation. J Exp Med. 2006;203(11):2473-83.
  1. Sengupta D, Koblansky A, Gaines J, Brown T, West AP, Zhang D, et al. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL. J Immunol Res. 2010;184(2):956-64.
  2. Wang X, Lin Z, Wei Q, Jiang Y, Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int. 2009;29(11):1343-7.